Biofarm (BSE:BIO) Construction In Progress: lei14.3 Mil (As of Mar. 2026)


BSE:BIO Biofarm SA BSE:BIO
69 GF Score
Price lei1.37
GF Value lei0.87
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biofarm Construction In Progress?

Biofarm BSE:BIO +0.74% 69 Construction In Progress is lei14.3 Mil as of Mar. 2026. GuruFocus rates BSE:BIO with a GF Score™ of 69/100 and a GF Value™ of lei0.87 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Biofarm's quarterly construction in progress declined from Sep. 2025 (lei11.3 Mil) to Dec. 2025 (lei11.1 Mil) but then increased from Dec. 2025 (lei11.1 Mil) to Mar. 2026 (lei14.3 Mil).

Biofarm's annual construction in progress declined from Dec. 2023 (lei56.2 Mil) to Dec. 2024 (lei50.8 Mil) and declined from Dec. 2024 (lei50.8 Mil) to Dec. 2025 (lei11.1 Mil).

Biofarm Construction In Progress Historical Data

* Premium members only.

The historical data trend for Biofarm's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofarm Construction In Progress Chart

Biofarm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.79 0.00 56.18 50.77 11.09

Biofarm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.02 52.71 11.32 11.09 14.32
BSE:BIO
69GF Score
Biofarm SA BSE:BIO
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofarm Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of lei14.3 Mil mean?
Biofarm (BSE:BIO) has a Construction In Progress of lei14.3 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Biofarm and its competitors.
Is Biofarm's Construction In Progress too high?
Biofarm's current Construction In Progress is lei14.3 Mil. Overall, Biofarm has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Construction In Progress compare to ZTS and UTHR?
Biofarm's Construction In Progress of lei14.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Biofarm and its competitors. Biofarm's current Construction In Progress is lei14.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.87, compared to a current price of lei1.37 — trading 57.5% above its estimated fair value. The current Construction In Progress is lei14.3 Mil. Biofarm's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current Construction In Progress is lei14.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofarm (BSE:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei1.37 is trading 57.5% above its estimated GF Value™ of lei0.87. GuruFocus considers Biofarm to be Significantly Overvalued.

Key valuation signals for BSE:BIO:

  • Construction In Progress: lei14.3 Mil
  • GF Value™: lei0.87 vs. price of lei1.37 (57.5% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofarm Business Description

Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score

Get the complete analysis for BSE:BIO

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei1.37
Price
lei0.87
GF Value